tradingkey.logo

Penumbra Inc

PEN
View Detailed Chart

256.500USD

+3.099+1.22%
Close 06/13, 16:00ETQuotes delayed by 15 min
9.92BMarket Cap
708.13P/E TTM

Penumbra Inc

256.500

+3.099+1.22%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.22%

5 Days

-0.93%

1 Month

-6.84%

6 Months

+4.46%

Year to Date

+8.01%

1 Year

+36.60%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 19 analysts
BUY
Current Rating
318.938
Target Price
24.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

112
Total
7
Median
9
Average
Company name
Ratings
Analysts
Penumbra Inc
PEN
19
Medtronic PLC
MDT
34
Stryker Corp
SYK
33
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
28
Dexcom Inc
DXCM
27
1
2
3
...
23

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(6)
Neutral(2)
Buy(5)
Indicators
Sell(3)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.983
Sell
RSI(14)
38.121
Neutral
STOCH(KDJ)(9,3,3)
35.398
Buy
ATR(14)
6.896
High Vlolatility
CCI(14)
-58.708
Neutral
Williams %R
74.449
Sell
TRIX(12,20)
-0.464
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
255.086
Buy
MA10
256.156
Buy
MA20
264.001
Sell
MA50
275.334
Sell
MA100
275.093
Sell
MA200
249.129
Buy

News

More news coming soon, stay tuned...

Company

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Ticker SymbolPEN
CompanyPenumbra Inc
CEOMr. Adam Elsesser, J.D.
Websitehttps://www.penumbrainc.com/
KeyAI